Discover
CYTK
Cytokinetics, Incorporated
87.09
3 x 62.59
1 x 111.32
bid
ask
+
1.83
2.15%
11:24 AM
timesize
| Ytd | 37.07% | |
| 1y | 153.47% |
84.63
day range
87.38
32.89
52 week range
88.31
| Open | 85.55 | Prev Close | 85.26 | Low | 84.63 | High | 87.38 | Mkt Cap | 11.81B |
| Vol | 351.32K | Avg Vol | 2.56M | EPS | -6.85 | P/E | N/A | Forward P/E | -18.24 |
| Beta | 0.43 | Short Ratio | 8.60 | Inst. Own | 118.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 73.62 | 200-d Avg | 64.96 | 1yr Est | 105.60 |
| Income Statement | |||
| Total Revenue | 19.36M | ||
| Revenues (USD) | 19.36M | ||
| Cost of Revenue | 2.55M | ||
| Gross Profit | 16.80M | ||
| Operating Expenses | 200.42M | ||
| Research and Development Expense | 95.53M | ||
| Selling, General and Administrative Expense | 104.90M | ||
| Operating Income | -183.62M | ||
| Interest Expense | 14.52M | ||
| Net Income | -206.03M | ||
| Net Income Common Stock | -206.03M | ||
| Net Income Common Stock (USD) | -206.03M | ||
| Consolidated Income | -206.03M | ||
| Earnings per Basic Share | -1.67 | ||
| Earnings per Basic Share (USD) | -1.67 | ||
| Earnings per Diluted Share | -1.67 | ||
| Earning Before Interest & Taxes (EBIT) | -191.51M | ||
| Earning Before Interest & Taxes (USD) | -191.51M | ||
| Weighted Average Shares | 123.27M | ||
| Weighted Average Shares Diluted | 123.27M | ||
| Balance Sheet | |||
| Cash and Equivalents | 129.84M | ||
| Cash and Equivalents (USD) | 129.84M | ||
| Investments | 943.43M | ||
| Investments Current | 688.71M | ||
| Investments Non-Current | 254.72M | ||
| Trade and Non-Trade Receivables | 6.83M | ||
| Current Assets | 839.47M | ||
| Property, Plant & Equipment Net | 156.98M | ||
| Total Assets | 1.27B | ||
| Debt Current | 65.77M | ||
| Total Debt | 1.29B | ||
| Current Liabilities | 199.19M | ||
| Debt Non-Current | 1.22B | ||
| Total Liabilities | 2.10B | ||
| Accumulated Retained Earnings (Deficit) | -3.69B | ||
| Accumulated Other Comprehensive Income | -1.61M | ||
| Shareholders Equity | -826.57M | ||
| Shareholders Equity (USD) | -826.57M | ||
| Assets Non-Current | 434.01M | ||
| Total Debt (USD) | 1.29B | ||
| Deferred Revenue | 1.65M | ||
| Inventory | 4.00M | ||
| Liabilities Non-Current | 1.90B | ||
| Trade and Non-Trade Payables | 24.71M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 3.38M | ||
| Net Cash Flow from Financing | 7.77M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 7.32M | ||
| Capital Expenditure | -5.93M | ||
| Issuance (Purchase) of Equity Shares | 11.35M | ||
| Issuance (Repayment) of Debt Securities | -2.73M | ||
| Net Cash Flow from Investing | 145.49M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 151.42M | ||
| Net Cash Flow from Operations | -145.46M | ||
| Effect of Exchange Rate Changes on Cash | -483.00K | ||
| Share Based Compensation | 30.39M | ||